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Objectives: Obesity is associated with an increased risk of breast cancer, and is 
also positively associated with tumor size and a higher probability of having posi-
tive axillary lymph nodes and faster growing tumors. It has been suggested that up 
to 50 % of postmenopausal breast cancers are attributable to obesity. Accordingly, 
this study assessed the impact of lifestyle intervention on body mass index (BMI) 
in women with breast cancer. MethOds: This is a randomized clinical trial study 
.The Study samples were 80 women with stage I, II, or III breast cancer, that oper-
ated for breast cancer and their chemotherapy or radiation therapy completed 3-18 
months ago. They are divided randomly into two groups; control group and lifestyle 
interventions group. Those in the lifestyle intervention group were instructed to 
practice aerobic exercises 45-60 minutes three times per week for 24 weeks with 
dietary energy restriction training. Those in the control group were instructed to 
continue normal activities and their routine health care. Data were obtained from 
the patient information form and body mass index form that completed before and 
after the lifestyle intervention in both groups. Results: No baseline differences 
existed between the two groups for the mean of BMI (p = 0.366) before the study 
; but the mean of BMI in the lifestyle intervention group after the intervention 
decreased to 25.12 ± 2.86, while in the control group it increased to 30.42 ± 6.89. The 
difference between the mean of BMI among the two groups after the intervention 
was statistically high (p = < 0.001). cOnclusiOns: Lifestyle intervention could be 
considered as part of a cancer survivorship program. For women with breast cancer, 
lifestyle intervention can decrease body mass index. Additional research in lifestyle 
intervention along with cognitive behavioral therapy also may be beneficial.
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Objectives: Minimally invasive hysterectomy using the Da Vinci robot-assisted 
surgical system remains uncertain if the technology offers benefits compared with 
traditional laparotomy. The aim of this study was to compare effectiveness and safety 
of robot-assisted laparoscopic hysterectomy (RALH) compared with traditional lapa-
rotomy in endometrial cancer. MethOds: We searched potentially relevant studies 
using Ovid-Medline, Ovid-EMBASE, Cochrane library, and 5 local medical databases 
through May 2014. The outcomes were overall complications, peri-operative complica-
tions, post-operative complications and specific morbidities for safety outcomes, sur-
vival, recurrence, length of stay (LOS), estimated blood loss (EBL), operative time (OT) 
for effectiveness outcomes. Two independent reviewers extracted data and assessed 
the risk of bias for non-randomized studies. Results: 19 eligible comparative studies 
representing 3,062 patients were identified. Overall and disease-free survival didn’t 
results in significant difference for 1 study. Pooled mean difference for resected total 
lymph nodes (LNs), pelvic LNs and aortic LNs showed no significant difference (WMD 
1.59, 95% CI -1.64-4.83, I2= 90%; WMD -1.64, 95% CI -4.21-0.94, I2= 91%; WMD 0.96, 95% 
CI -1.30-3.23, I2= 93%, respectively). LOS and OT was shorter for RALH (WMD -2.85, 
95% CI -3.28, -2.41, I2= 91%; WMD 44.15, 95% CI 20.91, 67.39, I2= 98%, respectively). 
EBL was significantly reduced in RALH group (WMD -159.62, 95% CI -189.73, -129.50, 
I2= 83%). Overall, intra-operative and post-operative complications (RR 0.37, 95% CI 
0.28-0.49, I2= 9%; RR 0.40, 95% CI 0.23-0.72, I2= 0%; RR 0.49, 95% CI 0.36-0.68, I2= 0%, 
respectively); the incidence of wound infection, wound dehiscence, wound com-
plications, ileus or bowel obstruction, infection, readmission, ICU stay, transfusion 
were significantly fewer but vaginal cuff dehiscence or separation were significantly 
higher in RALH than in laparotomy. Other individual peri-operative complications 
were similar. cOnclusiOns: RALH may be a generally safer and better option than 
laparotomy in endometrial cancer. Robotic surgery is associated with shorter LOS, 
OT; lower EBL and fewer complications than laparotomy. Further prospective studies 
with long term follow-up are required.
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Objectives: Patients with recurrent or metastatic SCCHN, particularly those with 
platinum-refractory disease, face limited treatment options that demonstrate dif-
ferentiated survival advantages and maintain or improve QoL. This study summa-
rized outcomes from systematically identified clinical studies reporting OS or QoL 
among patients with recurrent or metastatic SCCHN. MethOds: Eligible English-
language publications (01/2005–10/2014) were identified using EMBASE, MEDLINE, 
and the Cochrane Library. Results: Thirty-eight publications reporting clinical 
outcomes from 35 studies in all lines of therapy were identified (5902 patients). 
Most study arms received chemotherapy-based combinations. When stratified 
by prior treatment, median OS ranged from 7.4–11.1 months for platinum-naïve 
patients (11 arms), 4.3–11.8 months for platinum-refractory patients (12 arms), and 
5.0–32.2 months for patients with unspecified or mixed platinum history (38 arms). 
When stratified by current treatment regimen component, median OS ranged from 
4.3–12.4 months for cetuximab, 5.0–32.2 months for docetaxel, 5.2–6.7 months 
for methotrexate, and 4.3–19.1 months for paclitaxel. Among platinum-refractory 
patients, median OS ranged from 4.3–11.8 months for cetuximab, was 6.7 months 
for docetaxel and 5.2 months for methotrexate, and ranged from 4.3–11.7 months 
for paclitaxel. Fifteen studies reported QoL outcomes, including general-cancer 
and head-and-neck-specific QoL with impairments observed in domains includ-
ing eating, speech, appearance, and social impacts. Improvements, especially in 
pain, swallowing, and speech, were observed among platinum-naïve patients. 
However, among platinum-refractory patients, no statistically significant impacts 
on QoL were attributable to regimens including cetuximab or methotrexate, and 
no studies were identified reporting QoL outcomes with docetaxel or paclitaxel. 
line of treatment with a TKI (sunitinib, pazopanib, axitinib, or sorafenib) and/or 
mTOR inhibitor (everolimus or temsirolimus) during the study period (January 2012 
to February 2014) were identified by ICD9 code. Descriptive statistics were used to 
evaluate patterns of care in the overall sample. Univariate analysis was conducted to 
compare individual treatments. Multivariate analysis controlling for covariates will 
be shown in the poster. Results: 917 RCC patients meeting the study criteria were 
identified. Sunitinb (34%) was the most widely used drug followed by pazopanib 
(23%) and axitinib (14%). Mean duration of TKIs (3.7 mo) were higher than the mTOR 
(2.92) inhibitors (p= 0.004): sunitinib (3.87), pazopanib (3.67), axitinib (3.52), sorafenib 
(3.46), everolimus (3.12), and temsirolimus (2.58). Based on the univariate analysis 
there was statistically significant (p= 0.0054) but not clinically meaningful differ-
ence in duration across the individual treatments. cOnclusiOns: Real-world data 
analysis demonstrates significantly shorter duration of therapy of TKI and mTOR 
inhibitors than is published in clinical trials (range 4-8 months). Study results sug-
gest an unmet treatment need for RCC despite the rapid expansion of the number 
of drugs with an RCC indication in the past 5 years.
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Objectives: Approved treatment options for patients with recurrent GBM yield 
limited survival and QoL benefits. A systematic review was conducted to sum-
marize OS, QoL, and NF among patients with recurrent GBM. MethOds: Eligible 
English-language publications (01/2005–10/2014) were identified using EMBASE, 
MEDLINE, and the Cochrane Library. Results: Fifty publications were identified. 
Among bevacizumab-naïve patients treated with monotherapies, median OS ranged 
from 6.4–9.3 months with initial bevacizumab treatment, 6.6–9.4 months with other 
targeted therapies (enzastaurin, cediranib, and sunitinib), 7.1–11.7 months with 
chemotherapies (lomustine, verubulin, and temozolomide), and 10.9–11.4 months 
with the anti-hepatocyte growth factor monoclonal antibody rilotumumab. Among 
those treated with combination therapies, median OS ranged from 8.7–16.0 months 
with bevacizumab + chemotherapy, 5.6 months with bevacizumab + sorafenib, and 
9.4 months with cediranib + lomustine. Among patients with prior bevacizumab 
treatment, median OS was 3.4 months with verubulin, 4.4 months with sunitinib, 
and 3.4–3.6 months with rilotumumab. Among studies not specifically reporting 
outcomes for bevacizumab-naïve or -experienced patients, median OS ranged 
from 4.4 months with temsirolimus to 24.5 months with fotemustine. Factors that 
paralleled longer OS included male sex, younger age, fewer prior therapies, faster 
brain tissue diffusion on imaging, longer time to recurrence, smaller tumor volume, 
better performance status, and methylated O6-methylguanine-DNA methyltrans-
ferase promoter regions. Eight studies assessed the humanistic burden on patients. 
Baseline QoL and NF among these patients were worse compared with both the 
general population and patients with other cancers. No studies reported treatment-
related improvements in QoL or NF. cOnclusiOns: Currently available therapies 
for recurrent GBM are associated with limited OS duration and a lack of improve-
ments in QoL or NF. Among bevacizumab-naïve patients, initiation of bevacizumab 
or other mono- or combination therapies resulted in median OS less than 1.4 years, 
indicating a consistent unmet need in this population.
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Objectives: Initial treatment of chronic myeloid leukemia in chronic phase (CML-CP) 
is very important and tyrosine kinase inhibitors (TKIs) are effective to delay the pro-
gression of chronic phase in accelerated and blastic phase. Dasatinib and nilotinib 
have been compared to imatinib as first line treatments for CML in two recent ran-
domised studies. However, no head to head evidence exists of the relative efficacy of 
dasatinib and nilotinib. The purpose of this study is to compare the clinical effects 
between the three targeted agents in CML patients. MethOds: We conducted a sys-
tematic review and used the data extracted to perform an indirect comparison meta-
analysis of the three interventions. A random-effects approach was used to estimate 
the probability of response at each time point, and indirect comparison was imple-
mented in the WinBUGS software packages. Results: Data from nine clinical studies 
(3 trials) were included. The risk ratio of complete cytogenetic response (CCyR) and 
major molecular response (MMR) for dasatinib and nilotinib were significantly better 
than imatinib (CCyR and MMR at 6 months: 1.24 to 1.49 and 2.75 to 3.35; CCyR and 
MMR at 12 months: 1.18 to 1.23 and 1.50 to 1.99). A result of comparing the three TKIs 
of CCyR or MMR at 12 and 24 months’ follow-up through Bayesian indirect comparison 
nilotinib is the treatment showed a better response than the dasatinib (dasatinib vs. 
nilotinib at 24 months CCyR (95%CrI): 0.798 (0.300-0.986) vs. 0.844 (0.382-0.990); dasat-
inib vs. nilotinib at 24 months MMR (95%CrI): 0.604 (0.112-0.955) vs. 0.683 (0.173-0.970)).
The overall survival and progression-free survival were not significantly different 
compared to the imatinib. cOnclusiOns: On the basis of a systematic review of 
the current literature base, dasatinib and nilotinib should be viewed as dominant 
compared to imatinib. However, further clinical studies directly comparing nilotinib 
and dasatinib are required for more accurate comparisons between the three TKIs.
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